Samsung Bioepis Reports the Availability of Brenzys (biosimilar, etanercept) in Brazil

Samsung Bioepis, Reports, Availability, Brenzys, biosimilar, etanercept, Brazil


  • Samsung Bioepis reports the expansion of its global business with the entry of its first product, Brenzys (etanercept) in Brazil through Brazil’s public health system, Sistema Único de Saúde (SUS)
  • Samsung Bioepis signed a PDP agreement with Bionovis and Bio-Manguinhos/Fiocruz supplying Brenzis for the sales to SUS for a period of 10 years and will transfer its technology to the 2 companies enabling the manufacturing of Brenzys in Brazil 
  • Brenzys is a biosimilar of a reference product, Enbrel and has received ANVISA’s approval for RA, PsA, axSpA, AS and plaque Psoriasis in Dec’2017. Samsung Bioepis is expanding its business globally including China and collaborated with 3SBio & C-Bridge Capital to develop and commercialize its biosimilar candidates 

Click here to­ read full press release/ article | Ref: Samsung Bioepis | Image: BioPlus